16454-1 |
Beta galactosidase |
CCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Beta galactosidase [Enzymatic activity/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
umol/h/L |
|
|
|
|
|
|
CHEM |
|
16454-1 |
|
|
|
|
Both |
|
|
|
0 |
B-Galactosidase Bld-cCnc |
|
|
|
Y |
|
B; B-Galactosidase; Blood; Catalytic Concentration; Chemistry; Disaccharidase; GM 1-gangliosidosis; Lactase; Morquio disease type B; MPS IV B; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0l |
|
|
|
|
|
|
|
umol/h/L |
|
|
|
0 |
16455-8 |
Beta hydroxybutyrate |
SCnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Beta hydroxybutyrate [Moles/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16455-8 |
|
|
|
|
Both |
|
|
|
0 |
B-OH-Butyr CSF-sCnc |
|
|
|
Y |
|
3-hydroxybutyrate; 3-hydroxybutyric acid; B; Beta hydroxy butyrate; Beta hydroxybutyric acid; Betahydroxybutyrate; Betahydroxybutyric acid; BHB; BOHB; B-OH-Butyr; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Hydroxybutyric acid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Substance concentration |
2.34 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
16456-6 |
Beta hydroxybutyrate |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Beta hydroxybutyrate [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16456-6 |
|
|
|
|
Both |
|
|
|
0 |
B-OH-Butyr Ur-sCnc |
|
|
|
Y |
|
3-hydroxybutyrate; 3-hydroxybutyric acid; B; Beta hydroxy butyrate; Beta hydroxybutyric acid; Betahydroxybutyrate; Betahydroxybutyric acid; BHB; BOHB; B-OH-Butyr; Chemistry; Hydroxybutyric acid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
16457-4 |
Beta-N-acetylhexosaminidase.A |
CCnc |
WBC |
Pt |
Qn |
|
|
ACTIVE |
Beta-N-acetylhexosaminidase.A [Enzymatic activity/volume] in Leukocytes |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16457-4 |
|
|
|
|
Both |
|
|
|
0 |
Hexosaminidase A WBC-cCnc |
|
|
|
Y |
|
B; Beta-hexosaminidase subunit alpha; B-NAH; Catalytic Concentration; Chemistry; GM2 Gangliosidoses; GM2-gangliosidosis; Hex A; Hex B; HEXA; Hexosaminidase; Hexosaminidase A; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; Sandhoff disease; Tay Sachs Disease; WBCs; White blood cells |
2.73 |
1.0l |
|
|
|
|
|
|
|
nmol/mL/min |
|
|
|
0 |
16458-2 |
Bethanechol |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bethanechol [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16458-2 |
|
|
|
|
Both |
|
|
|
0 |
Bethanechol SerPl-mCnc |
|
|
|
Y |
|
1-Propanaminium; C7H17ClN2O2; DRUG/TOXICOLOGY; Drugs; Duvoid; Level; Mass concentration; Myotonine; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Urabeth; Urecholine |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16459-0 |
Bicarbonate |
SCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16459-0 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 Fld-sCnc |
|
|
|
Y |
|
B/F; BF; BIC; bicar; Bicarb; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; Fl; Fld; FLU; Fluid; HCO3; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.34 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
1646-9 |
Xylose^post dose PO |
MRat |
Urine |
5H |
Qn |
|
|
ACTIVE |
Xylose [Mass/time] in 5 hour Urine --post dose PO |
|
MIN |
DefinitionDescription |
|
|
g/5 H |
|
|
|
|
|
|
CHAL |
|
1646-9 |
|
|
|
|
Observation |
|
|
|
0 |
Xylose p PO 5h Ur-mRate |
|
|
|
Y |
|
5 hours; 5.0Hr; 5HR; After; CHEMISTRY.CHALLENGE TESTING; D-xylose; Mass rate; mRate; p dose; p PO; PST; QNT; Quan; Quant; Quantitative; UA; UR; Urn; Xylose absorption test |
2.73 |
1 |
|
|
|
|
|
|
|
g/(5.h) |
|
|
|
0 |
16460-8 |
Bicarbonate |
SCnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16460-8 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 CSF-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; HCO3; Level; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Substance concentration |
2.34 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
16461-6 |
Bicarbonate |
SCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16461-6 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 RBC-sCnc |
|
|
|
Y |
|
BIC; bicar; Bicarb; Chemistry; Erythrocytes; HCO3; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Substance concentration |
2.34 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
16462-4 |
Bicarbonate |
SCnc |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Bicarbonate [Moles/volume] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
16462-4 |
|
|
|
|
Both |
|
|
|
0 |
HCO3 Amn-sCnc |
|
|
|
Y |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; BIC; bicar; Bicarb; Chemistry; Gyn; Gynecology; HCO3; Level; OB; ObGyn; Obstetrics; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.34 |
1.0l |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
16463-2 |
Bile acid.dihydroxy |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bile acid.dihydroxy [Mass/volume] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
CHEM |
|
16463-2 |
|
|
|
|
Both |
|
|
|
0 |
Di-OH Bile Ac SerPl-mCnc |
|
|
|
Y |
|
Acd; Acids; Bile acid.total; Bile salt; Chemistry; Di-OH Bile Ac; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.67 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
Release 2.67: SYSTEM: Added Plas because this test can be run on both serum and plasma |
0 |
16464-0 |
Bile acid |
ACnc |
Exhl gas |
Pt |
Qn |
|
|
ACTIVE |
Bile acid [Units/volume] in Exhaled gas |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16464-0 |
|
|
|
|
Both |
|
|
|
0 |
Bile Ac ExG-aCnc |
|
|
|
Y |
|
Acd; Acids; Arbitrary concentration; Bile acid.total; Bile salt; Breath; Chemistry; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16465-7 |
Bile acid |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Bile acid [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16465-7 |
|
|
|
|
Both |
|
|
|
0 |
Bile Ac Ur-mCnc |
|
|
|
Y |
|
Acd; Acids; Bile acid.total; Bile salt; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16466-5 |
Bile acid.trihydroxy |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Bile acid.trihydroxy [Mass/volume] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
CHEM |
|
16466-5 |
|
|
|
|
Both |
|
|
|
0 |
Tri-OH Bile Ac SerPl-mCnc |
|
|
|
Y |
|
Acd; Acids; Bile acid.total; Bile salt; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri OH; Tri-OH; Tri-OH Bile Ac |
2.67 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
Release 2.67: SYSTEM: Added Plas because this test can be run on both serum and plasma |
0 |
16467-3 |
Bismuth |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Bismuth [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16467-3 |
|
|
|
|
Both |
|
|
|
0 |
Bismuth Bld Ql |
|
|
|
|
|
BI; Blood; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16468-1 |
Bismuth |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Bismuth [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16468-1 |
|
|
|
|
Both |
|
|
|
0 |
Bismuth Ur Ql |
|
|
|
|
|
BI; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16469-9 |
Bismuth/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Bismuth/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/g creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
16469-9 |
|
|
|
|
Both |
|
|
|
0 |
Bismuth/Creat Ur |
|
|
|
Y |
|
BI; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/g{creat} |
|
|
|
0 |
1647-7 |
Tuberculosis reaction wheal^3D post 25 TU ID |
Diam |
Skin |
Pt |
Qn |
|
|
ACTIVE |
Tuberculosis reaction wheal [Diameter] --3 days post 25 TU intradermal |
|
MIN |
DefinitionDescription |
|
|
mm |
|
|
|
|
|
|
CHALSKIN |
|
1647-7 |
|
|
|
|
Observation |
|
|
|
0 |
TB Wheal 3D p 25 TU Diam |
|
|
|
Y |
|
2nd strength PPD; 3D p 25 TU; After; Dermatologic; Diameter; Epidermis; Identifier; Integument; Intradermal; Point in time; PPD; PST; Purified protein derivative skin test; Purified protein derivative test; QNT; Quan; Quant; Quantitative; Random; React; Rx wheal; Rxn; Skin test; SKIN TESTS; Skn; TB; TB skin test; TB Wheal; TST; Tubeculin Units |
2.26 |
1 |
|
|
|
|
|
|
|
mm |
|
|
|
0 |
16470-7 |
Blastomyces dermatitidis Ab |
PrThr |
Ser |
Pt |
Ord |
Comp fix |
|
ACTIVE |
Blastomyces dermatitidis Ab [Presence] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16470-7 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
B dermat Ab Ser Ql CF |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B dermat; B dermatitidis; Blasto; Blastomycosis; CF; Comp fixation; Compfix; Complement fixation; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16471-5 |
Blastomyces dermatitidis Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Blastomyces dermatitidis Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16471-5 |
|
|
|
|
Both |
|
|
|
0 |
B dermat Ab Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B dermat; B dermatitidis; Blasto; Blastomycosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16472-3 |
Blastomyces dermatitidis rRNA |
PrThr |
Ser |
Pt |
Ord |
Probe |
|
ACTIVE |
Blastomyces dermatitidis rRNA [Presence] in Serum by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16472-3 |
|
Probe |
|
|
Both |
|
|
|
0 |
B dermat rRNA Ser Ql Probe |
|
|
|
|
|
B dermat; B dermatitidis; Blasto; Blastomycosis; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; Serum; SR |
2.63 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. In the Short Name 'Prb' was changed to 'Probe' for clarity. |
0 |
16473-1 |
Bordetella parapertussis Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Bordetella parapertussis Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16473-1 |
|
|
|
|
Both |
|
|
|
0 |
B parapert Ab Ser-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B parapert; B parapertussis; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Whooping cough |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16474-9 |
Bordetella pertussis Ab |
ACnc |
Ser |
Pt |
Qn |
Comp fix |
|
ACTIVE |
Bordetella pertussis Ab [Units/volume] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16474-9 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
B pert Ab Ser CF-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B pert; B pertussis; CF; Comp fixation; Compfix; Complement fixation; ID; Infectious Disease; InfectiousDisease; Microbiology; Pertussis; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Whooping cough |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16475-6 |
Borrelia burgdorferi Ab |
PrThr |
CSF |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16475-6 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor Ab CSF Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Burgdorf; Cerebral spinal fluid; Cerebrospinal Fl; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
16476-4 |
Borrelia burgdorferi Ab |
PrThr |
Body fld |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi Ab [Presence] in Body fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16476-4 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor Ab Fld Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; B/F; Bb; BF; bod; Bodies; Body fluid; Body fluid, unsp; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; Fl; Fld; FLU; Fluid; IAA; ID; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SUDS |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |